XRAY DENTSPLY SIRONA Inc. Insider Trading

Director Clyde Hosein buys 6,500 shares of XRAY at $9.98; 4 other insiders bought within 14 days amid -3.0% revenue decline, unprofitable year.

Clyde Hosein purchased 6,500 shares at $9.98 on 2026-06-15, increasing his holdings by 10.1% from 64.1K to 70.6K shares. This transaction is part of a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated internal interest despite operating headwinds. The company reported net income of $-10.0M on revenue of $880.0M in its latest quarter, with annual revenue growth of -3.0%, indicating the firm is unprofitable and contracting. The stock currently trades at $10.45, down 38.8% from its 52-week high of $17.09, creating a significant valuation gap that may be attracting director-level accumulation at depressed levels.

Director Brian P McKeon buys 10,000 shares of XRAY at $10.12; cluster of 2 other insider buys in 14 days.

Brian P McKeon, a Director, purchased 10,000 shares at $10.12 on 2026-06-12, representing his first position in XRAY. This transaction occurs within a cluster pattern: 2 other insiders also bought within the past 14 days. Notably, McKeon's cross-ticker track record shows 9 prior sells with a 90d well-timed rate of 100.00%, indicating those prior dispositions preceded stock declines. The company context is material: XRAY reported net income of $-10,000,000.00 in its most recent fiscal year (unprofitable), revenue declined -3.0% year-over-year, and the stock trades at $10.14, down 40.7% from its 52-week high of $17.09. The simultaneous buying by multiple insiders at a depressed valuation level warrants investor attention to management's assessment of company stability and recovery prospects.

Director Brian Gladden buys 9,985 shares of XRAY at $10.02; cluster of 3 other insiders buying within 14 days amid -40.7% drawdown from 52-week high.

Brian Gladden purchased 9,985 shares for $100,000.00 at $10.02 on 2026-06-15, bringing his holdings from 51.9K to 61.8K shares (+19.3% increase in position size). This buy occurs within a 14-day cluster in which 3 other insiders also purchased shares. Notably, the company is currently unprofitable (full-year net income was negative) with annual revenue declining -3.0%, and the stock is trading -40.7% from its 52-week high of $17.09 while down -17.0% over the past 90 days. The convergence of multiple insider purchases during a period of weak fundamentals and depressed valuation warrant investor attention to whether insiders perceive value at current levels or whether further deterioration is possible.

Director Betsy D Holden buys 10,086 shares of XRAY at $9.88; stock down 40.7% from 52-week high, company unprofitable

Betsy D Holden, a director of DENTSPLY SIRONA, purchased 10,086 shares at $9.88, increasing her holding by 13.0% from 77,442 to 87,528 shares. The purchase price sits near the 52-week low ($9.40), while the stock trades 40.7% below its 52-week high of $17.09, suggesting the transaction occurred during a depressed period for the equity. The company's recent fundamentals present a contrasting picture: DENTSPLY generated $880.0M in quarterly revenue but posted a net loss of $10.0M, with annual revenue declining 3.0% year-over-year and a $2.0B market cap. The director's accumulation at a low absolute price point—concurrent with negative profitability and revenue contraction—presents a transaction investors should track alongside emerging turnaround signals or forward guidance.

Director Michael J Barber buys 15.2K shares of XRAY at $9.88; stock down -40.7% from 52-week high amid -3.0% revenue decline and recent unprofitability.

Michael J Barber increased his holdings by 37.2% with a $150,004.88 purchase at $9.88 per share, accumulating to 55,943 shares post-transaction. The acquisition occurs at a significant discount to the 52-week high of $17.09 and reflects a reversal from the stock's recent 90-day decline of -17.0%. Contextually, DENTSPLY SIRONA reported a net loss of $-10,000,000.00 in its latest quarter and negative annual revenue growth of -3.0%, indicating operational headwinds. The director's substantial accumulation in the face of compressed fundamentals and depressed valuation relative to recent trading ranges warrants attention as a signal of insider conviction, though the absence of broader insider activity limits the evidentiary weight of a single actor's positioning.

Director Forbes buys 5,000 XRAY shares at $12.48; doubles holdings to 10,000 shares amid -3.0% annual revenue decline, $-427.0M net loss.

Forbes James D purchased 5,000 shares at $12.48 on 2026-03-09, doubling his holdings from 5,000 to 10,000 shares and committing $62,400.00 to the position. This purchase occurred six days after a prior XRAY buy on 2026-03-03, indicating consecutive accumulation at depressed levels—the stock is currently trading at $12.80, down 24.0% from its 52-week high of $16.85. However, the company's fundamentals present significant headwinds: annual revenue declined 3.0% to $904.0M, and net income for the most recent full fiscal year was negative at $-427.0M, signaling operational distress that extends beyond temporary market weakness. The rapid succession of purchases by a director warrants attention, but without disclosure of his strategic rationale or knowledge of material developments, the timing of accumulation into a structurally unprofitable business cannot be isolated from broader market and company risk factors.

Director LUCIER GREGORY T buys 15,000 shares of XRAY at $12.44 on 2026-03-09; stock down -24.0% from 52-week high; company unprofitable.

Director Lucier Gregory T purchased 15,000 shares at $12.44 on 2026-03-09, increasing his stake by 30.0% to 65,000 shares total. The transaction occurs at a material discount to the 52-week high of $16.85, with the stock currently trading -24.0% below that peak and -7.0% lower over the past 30 days. However, the company's fundamentals remain challenged: it posted a net income of $-427,000,000.00 against revenue of $904,000,000.00 in the latest quarter and reported annual revenue contraction of -3.0% on a year-over-year basis. Looking at his prior trades at XRAY specifically, the timing pattern has been mixed—just 1 of his 3 measurable prior buys at this ticker achieved positive 90-day returns. This purchase enters a volatile stock environment against a backdrop of unprofitable operations.

Director LUCIER GREGORY T buys 50,000 shares at blended $14.15 across 2 transactions, establishing initial position

Director LUCIER GREGORY T executed 2 separate purchases totaling 50,000 shares for $707,379.44 ($707.4K) on 2026-03-02 and 2026-03-03, establishing a new 50.0K share position from zero prior holdings. The stock is currently trading at $13.30, down 29.3% from its 52-week high of $18.81, though it has risen 6.7% over the past 30 days and 17.3% over 90 days. At XRAY specifically, LUCIER's prior 5 purchases show a mixed track record: only 1 of 5 prior buys produced positive 90-day returns, suggesting weak timing accuracy at this ticker historically. The company's fundamentals are strained, with latest quarterly revenue of $904,000,000.00 declining 3.0% year-over-year and full-year net income of -$427,000,000.00 reflecting ongoing unprofitability. The new purchase occurs during a recovery phase but against a backdrop of weak corporate financial performance and the insider's historically poor 90-day timing results at this specific stock.

Director James D Forbes purchases 5,000 shares of XRAY at $13.47; stock now $13.30, down -29.3% from 52-week high of $18.81.

Director James D Forbes initiated a position in DENTSPLY SIRONA with a purchase of 5,000 shares at $13.47 on 2026-03-03, establishing his first recorded holding in the company. The transaction occurs in an environment where the stock has declined significantly from its 52-week high of $18.81 (now trading at $13.30, -29.3% from peak) and the company reported a net loss of $427.0M in its most recent quarter alongside negative annual revenue growth of -3.0%. The entry by a director warrants monitoring given the company's unprofitable state, though the scale of the initial purchase (5,000 shares for $67.3K) and recent positive momentum (30-day change: +6.7%, 90-day change: +17.3%) provide limited basis for drawing strong conclusions about directional conviction at this stage.

Director Varon Leslie F buys 9,337 shares of XRAY at $10.71 (+19.4% to holdings) despite -427.0M net loss and -4.3% revenue decline.

Director Varon Leslie F purchased 9,337 shares at $10.71 for a total value of $99,999.27, increasing his holdings by 19.4% from 48,005 to 57,342 shares. The purchase occurs in a context of material corporate stress: the company reported a net loss of $-427.0M in its most recent fiscal year and annual revenue contraction of -4.3%, with the stock trading at -45.4% from its 52-week high of $20.31. The timing relative to price momentum is notable: the stock has declined -15.4% over 30 days and -22.6% over 90 days, and currently trades at $11.09, only 3.5% above the transaction price. This is a discretionary open-market purchase by a director accumulating more than 9,000 shares into a company facing both operational headwinds and significant equity value destruction.